Barclays PLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Kiniksa Pharmaceuticals, Ltd. stock. As of the latest transaction made, Barclays PLC holds 34,839 shares of KNSA stock, worth $748,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,839

Previous 42,147 17.34%

Holding current value

$748,341

Previous $831,000 21.78%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$16.88 - $20.33 $123,359 - $148,571	-7,308 Reduced 17.34%	34,839 $650,000
Q1 2024 May 15, 2024	SELL	$17.63 - $21.74 $2.53 Million - $3.12 Million	-143,609 Reduced 77.31%	42,147 $831,000
Q4 2023 Feb 15, 2024	BUY	$14.37 - $19.07 $147,019 - $195,105	10,231 Added 5.83%	185,756 $3.26 Million
Q3 2023 Nov 07, 2023	BUY	$13.62 - $20.2 $175,248 - $259,913	12,867 Added 7.91%	175,525 $3.05 Million
Q2 2023 Aug 03, 2023	BUY	$10.44 - $16.48 $5,000 - $7,893	479 Added 0.3%	162,658 $2.29 Million
Q1 2023 May 04, 2023	BUY	$10.7 - $15.79 $1.09 Million - $1.61 Million	102,172 Added 170.27%	162,179 $1.75 Million
Q4 2022 Feb 13, 2023	BUY	$11.42 - $17.05 $430,145 - $642,205	37,666 Added 168.6%	60,007 $899,000
Q3 2022 Nov 03, 2022	BUY	$9.76 - $13.41 $58,257 - $80,044	5,969 Added 36.46%	22,341 $287,000
Q2 2022 Aug 12, 2022	SELL	$7.6 - $11.41 $24,996 - $37,527	-3,289 Reduced 16.73%	16,372 $158,000
Q1 2022 May 16, 2022	SELL	$9.3 - $12.37 $333,618 - $443,749	-35,873 Reduced 64.6%	19,661 $195,000
Q4 2021 Feb 14, 2022	SELL	$10.39 - $15.15 $218,460 - $318,543	-21,026 Reduced 27.46%	55,534 $653,000
Q3 2021 Nov 09, 2021	BUY	$11.39 - $16.23 $646,166 - $920,744	56,731 Added 286.1%	76,560 $872,000
Q2 2021 Aug 13, 2021	SELL	$13.22 - $19.09 $3.12 Million - $4.5 Million	-235,707 Reduced 92.24%	19,829 $275,000
Q1 2021 May 13, 2021	SELL	$16.68 - $23.97 $7.1 Million - $10.2 Million	-425,364 Reduced 62.47%	255,536 $4.73 Million
Q4 2020 Feb 11, 2021	BUY	$14.8 - $21.15 $5.81 Million - $8.3 Million	392,512 Added 136.11%	680,900 $12 Million
Q3 2020 Nov 12, 2020	BUY	$15.21 - $25.53 $4.13 Million - $6.94 Million	271,796 Added 1638.11%	288,388 $4.42 Million
Q2 2020 Aug 12, 2020	BUY	$15.08 - $26.0 $156,334 - $269,542	10,367 Added 166.54%	16,592 $423,000
Q1 2020 May 13, 2020	SELL	$11.0 - $19.76 $132,638 - $238,266	-12,058 Reduced 65.95%	6,225 $97,000
Q4 2019 Feb 10, 2020	BUY	$5.24 - $12.96 $35,967 - $88,957	6,864 Added 60.11%	18,283 $202,000
Q3 2019 Nov 14, 2019	BUY	$8.15 - $15.88 $2,151 - $4,192	264 Added 2.37%	11,419 $98,000
Q2 2019 Aug 14, 2019	BUY	$13.2 - $20.39 $89,628 - $138,448	6,790 Added 155.56%	11,155 $151,000
Q1 2019 May 15, 2019	BUY	$15.93 - $26.59 $20,884 - $34,859	1,311 Added 42.93%	4,365 $80,000
Q4 2018 Feb 14, 2019	BUY	$16.25 - $28.09 $10,140 - $17,528	624 Added 25.68%	3,054 $86,000
Q3 2018 Nov 14, 2018	BUY	$13.23 - $30.93 $32,148 - $75,159	2,430 New	2,430 $62,000

Others Institutions Holding KNSA

# of Institutions

Shares Held

1.99M

Call Options Held

Put Options Held

View Full List

About Kiniksa Pharmaceuticals, Ltd.

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $740M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

More about KNSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account